| Examiner | Number of Cases | 3YGR |
|---|---|---|
| Examiner Abbas | 34 | 0% |
| Examiner Carter | 248 | 47% |
| Examiner Chandra | 381 | 69% |
| Examiner Ford (SPE) | 39 | 0% |
| Examiner Howard | 402 | 67% |
| Examiner Kaufman | 249 | 60% |
| Examiner Li | 435 | 67% |
| Examiner Mccollum | 311 | 44% |
| Examiner Mertz | 479 | 73% |
| Examiner Middleton | 50 | 34% |
| Examiner Pak | 233 | 54% |
| Examiner Schwechter | 0 | 0% |
| Examiner Xie | 253 | 48% |
| Examiner Yang | 0 | 0% |
| Art Unit 1674 | 3114 | 59% |
| Number | Class Description |
|---|---|
| 424 | Drug, bio-affecting and body treating compositions |
| 514 | Drug, bio-affecting and body treating compositions |
| 435 | Chemistry: molecular biology and microbiology |
| 530 | Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof |
| 536 | Organic compounds -- part of the class 532-570 series |
| 436 | Chemistry: analytical and immunological testing |
| 604 | Surgery |
| 506 | Combinatorial chemistry technology: method, library, apparatus |
| 930 | Peptide or protein sequence |
| 705 | Data processing: financial, business practice, management, or cost/price determination |
Art Unit 1674's grant rate is lower than that of Group 1670 and lower than that of the USPTO.
Below is the grant rate timeline for Art Unit 1674, where the timeline is relative to the date of the first office action. The three-year grant rate is the percentage of applications granted at three years after the first office action.
Disclaimer: We do not provide any guarantees as to the accuracy of the statistics presented above and under
no circumstances will we be liable for any outcome resulting from your reliance on the above statistics.